Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new WWARN study, published in BMC Medicine, supports a World Health Organization (WHO) recommendation that a single primaquine target dose of 0.25 mg/kg is generally safe and well tolerated when given together with an ACT to treat malaria.

Woman carrying a child, in a limited-resource settlement in Kenya © Peter Kapuscinski, World Bank

Primaquine has been available for more than 70 years and millions of doses have been administered over the years, but safety outcomes have not been well documented.

The WHO changed its guidelines to lower the dosage of primaquine in 2012, to accelerate malaria elimination efforts and avoid the spread of artemisinin resistance. However, uptake of the recommendation has been slow due to safety concerns among those with G6PD deficiency. G6PD deficiency is an inherited enzyme deficiency that is particularly common in some malaria endemic areas that makes red blood cells more likely to break down.

Researchers performed a systematic review and an individual patient data (IPD) meta-analysis of single dose (SD) primaquine studies for Plasmodium falciparum malaria with the aim of establishing the safety of SD primaquine, improving uptake and potentially setting guidelines for the implementation of weight or age-based dosing bands. The data included 20 studies of 6,406 participants, of which over 80% had received a single target dose of primaquine ranging between 0.0625 and 0.75 mg/kg. There was no effect of primaquine on haemoglobin concentrations (a measure for anaemia) in G6PD normal participants, and only a small effect on haemoglobin among the 194 G6PD-deficient African participants given a 0.25 mg/kg primaquine target dose.

The authors said the results could now reassure national malaria control programmes that were considering the use of SD primaquine to advance malaria elimination or reduce the spread of artemisinin resistance.

The full story is available on the WWARN website.

Read the full paper 'Safety of single dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data' on the BMC Medicine website

Similar stories

Bacterial infections linked to one in eight global deaths, according to GRAM study

Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings

GRAM visualization tool tracks country-level AMR and related metrics

Interactive app allows users to explore data underlying estimates of global AMR burden

MQRG team delivers training in Mozambique and Ghana

IDDO’s Medicine Quality Research Group delivered in-person training in researchers in Mozambique and Ghana to support a study into the quality of three antibiotics.

Studying the MSc IHTM 2022/23

MSc IHTM sets out to attract individuals from low resource contexts who are looking to gain the skills and experience to help shape global health in the future. This year 23 students make up the cohort bringing the running total over the eight years of the course to 175 students from 56 countries, the majority of which are LMICs.

The University of Oxford launches fully online Postgraduate Diploma in Global Health Research to tackle inequities in health research leadership

Beginning in October 2023, the Postgraduate Diploma in Global Health Research is specifically targeted at researchers and clinicians in low income countries, and will offer accessibility never previously available. It is the University’s first academic qualification designed to be taken wholly online and will transform Oxford’s ability to reach and train researchers in the most challenging of settings. By removing this significant barrier to access, the postgraduate diploma aims to strengthen health workforces’ research capacity, regardless of location and context, to meet ongoing and emerging global health challenges and crises.

Building Health Research Capacity in Seychelles through strengthened Collaboration

The MSc IHTM is committed to leading positive change in low resource contexts. The aim of the course is to provide students with the skills and opportunities to collaborate across cultural and disciplinary boundaries to identify and develop creative solutions for existing and emerging national, regional and/or global health challenges. A recent example of the impact of the MSc has been an initiative in Seychelles, where a partnership has been established between the MSc IHTM and the Seychelles Ministry of Health (MoH).